No Data
Argenx Announces Positive CHMP Opinion for VYVGART (Efgartigimod Alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Wells Fargo Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $741
Argenx Se's Revenue Growth Potential Boosted by Vyvgart Hytrulo's Market Impact and Increased Treatment Cycles
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS), Neurocrine (NBIX) and Argenx Se (ARGX)
What's Driving the Market Sentiment Around Argenx?
Argenx Price Target Lowered to EUR 680 From EUR 736 at BofA